Download Free Fast Facts Gynecologic Oncology Book in PDF and EPUB Free Download. You can read online Fast Facts Gynecologic Oncology and write the review.

Endometrial cancer (EC) is the most common cancer of the uterus and the only gynecologic malignancy that is increasing in incidence and mortality. Early-stage EC generally has a good prognosis but 5-year survival is poor for those with advanced-stage disease or recurrent disease. This resource provides the latest information on epidemiology, risk factors and diagnosis, including the implications of Lynch syndrome in younger women, and the latest thinking on classification, grading, staging and prognostic risk groups, made possible by major advances in the molecular characterization of EC. The therapeutic implications of these advances are still being discovered and here we outline the latest evidence-based therapies and management of the disease. Table of Contents: • Epidemiology and risk factors • Diagnosis • Grading, staging and prognosis • Molecular characterization • Treatment of early-stage disease • Management of advanced and recurrent disease • Research directions
PROLOG is a voluntary, strictly confidential, personal continuing education resource that is designed to be stimulating and enjoyable. By participating in PROLOG, obstetrician-gynecologists will be able to do the following: - Review and update clinical knowledge - Recognize areas of knowledge and practice in which they excel, be stimulated to explore other areas of the specialty, and identify areas requiring further study - Plan continuing education activities in light of identified strengths and deficiencies - Compare and relate present knowledge and skills with those of other participants - Obtain continuing medical education credit, if desired - Have complete personal control of the setting and of the pace of the experience The obstetrician-gynecologist who completes Gynecologic Oncology and Critical Care, Eighth Edition, will be able to - identify epidemiologic factors that contribute to the risks of various malignancies and determine appropriate screening tests. - analyze the pathophysiology and evaluate the histopathology of various malignancies. - associate symptoms with early onset of specific malignancies, determine appropriate diagnostic tests, and select diagnosis. -
When it comes to detecting, diagnosing and treating women who have, or are suspected of having, ovarian cancer, there are significant opportunities for well-informed healthcare professionals to intervene in a meaningful way. 'Fast Facts: Ovarian Cancer' examines the areas that will have the biggest effect in clinical practice, including: • the evidence for and against screening • the valuable role of genetic testing in identifying at-risk women • if and when to operate • strategies to overcome platinum resistance • the impact of targeted therapies. From the tools that will help establish a swift diagnosis to the risks and benefits of palliative salvage surgery, this refreshingly readable resource captures the key knowledge that every busy healthcare professional needs in order to make better health decisions for patients with ovarian cancer. Contents: • Epidemiology and prevention • Pathophysiology and classification • Genetic testing • Diagnosis, staging and grading • Surgery • Chemotherapy • Recurrent ovarian cancer • Targeted therapies • Non-epithelial ovarian cancers • Follow-up and palliative surgery • Useful resources
In den letzten Jahren kam es zu einem noch nie dagewesenen Anstieg unseres Wissens über das Management des Ovarialkarzinoms; von Diagnose und Genetik bis hin zur Operation und neuen zielgerichteten Behandlungsmethoden. Das bedeutet, dass sich für den gut informierten Mediziner in Bezug auf die Diagnose und Behandlung von Frauen mit Ovarialkarzinom oder dem Verdacht auf Ovarialkarzinom mehrere Möglichkeiten zur sinnvollen Intervention bieten. Dieses Buch bietet eine umfassende Übersicht über alle Versorgungsebenen, fasst die aktuellen Fortschritte zusammen und stellt sie in klinischen Kontext. Es beantwortet wichtige Fragen, wie wann operiert werden und wann eine Behandlung mit konventionellen bzw. mit neuartigen Modalitäten durchgeführt werden sollte. Inhalt: • Epidemiologie und Prophylaxe • Pathophysiologie und Klassifizierung • Gentests • Diagnose, Staging und Grading • Operation • Chemotherapie • Rezidivierendes Ovarialkarzinom • Zielgerichtete Therapien • Nicht-epitheliale Ovarialkarzinome • Nachsorge und palliative Operation • Hilfreiche Adressen
"Atlas of Staging in Gynecological Cancer" has a unique format. It is designed to be used in conjunction with diagnostic procedures between the surgeon and the radiologist. It describes the two common staging regimes, namely, the FIGO staging system and the TNM system.
Biologics have revolutionized – and are revolutionizing – the treatment of many serious disorders. The evidence acquired from more than 10 years of clinical experience, with more than 50 biosimilar drugs and more than 700 million patient-days' exposure in Europe, shows that approved biosimilars can be used as safely and effectively as originator biologics. Yet concerns persist about biosimilars – particularly in curative cancer treatment, where they are relatively recent therapeutic options. 'Fast Facts: Biosimilars in Hematology and Oncology' provides a concise overview of emerging global practice in this fast-moving area together with practical information on adding biosimilars to a formulary and switching patients. Contents: • Biologics and the need for biosimilars • Why do we need biosimilars? • How is the quality of biosimilar medicines assured? • Legal issues • Switching, interchangeability and extrapolation • Safety and pharmacovigilant • Global issues • Formulary considerations: pharmacy issues • Formulary considerations: supportive care biosimilars • Formulary considerations: therapeutic anti-cancer biosimilars • Communication and awareness
This book addresses the reality of delivering gynaecological care in the 21st century, and looks at the developments that are currently taking place in the field. It provides an overview of some common gynaecological problems and looks at new services and different ways of delivering care. It also shows how gynaecological services are developing in response to women's needs. Above all the book is not medically orientated but shows how nurses and professionals allied to medicine are making a difference. * Covers the latest developments in the gynaecological field * Written soecifically from a nursing and allied health professionals perspective
The latest edition of An Atlas of Gynecologic Oncology continues its coverage of the innovative techniques in investigation and surgery on the brink of becoming established as part of the gynecologic surgeon’s repertoire, now including the exciting developments in uterine transplantation.
#1 NEW YORK TIMES BESTSELLER • “The story of modern medicine and bioethics—and, indeed, race relations—is refracted beautifully, and movingly.”—Entertainment Weekly NOW A MAJOR MOTION PICTURE FROM HBO® STARRING OPRAH WINFREY AND ROSE BYRNE • ONE OF THE “MOST INFLUENTIAL” (CNN), “DEFINING” (LITHUB), AND “BEST” (THE PHILADELPHIA INQUIRER) BOOKS OF THE DECADE • ONE OF ESSENCE’S 50 MOST IMPACTFUL BLACK BOOKS OF THE PAST 50 YEARS • WINNER OF THE CHICAGO TRIBUNE HEARTLAND PRIZE FOR NONFICTION NAMED ONE OF THE BEST BOOKS OF THE YEAR BY The New York Times Book Review • Entertainment Weekly • O: The Oprah Magazine • NPR • Financial Times • New York • Independent (U.K.) • Times (U.K.) • Publishers Weekly • Library Journal • Kirkus Reviews • Booklist • Globe and Mail Her name was Henrietta Lacks, but scientists know her as HeLa. She was a poor Southern tobacco farmer who worked the same land as her slave ancestors, yet her cells—taken without her knowledge—became one of the most important tools in medicine: The first “immortal” human cells grown in culture, which are still alive today, though she has been dead for more than sixty years. HeLa cells were vital for developing the polio vaccine; uncovered secrets of cancer, viruses, and the atom bomb’s effects; helped lead to important advances like in vitro fertilization, cloning, and gene mapping; and have been bought and sold by the billions. Yet Henrietta Lacks remains virtually unknown, buried in an unmarked grave. Henrietta’s family did not learn of her “immortality” until more than twenty years after her death, when scientists investigating HeLa began using her husband and children in research without informed consent. And though the cells had launched a multimillion-dollar industry that sells human biological materials, her family never saw any of the profits. As Rebecca Skloot so brilliantly shows, the story of the Lacks family—past and present—is inextricably connected to the dark history of experimentation on African Americans, the birth of bioethics, and the legal battles over whether we control the stuff we are made of. Over the decade it took to uncover this story, Rebecca became enmeshed in the lives of the Lacks family—especially Henrietta’s daughter Deborah. Deborah was consumed with questions: Had scientists cloned her mother? Had they killed her to harvest her cells? And if her mother was so important to medicine, why couldn’t her children afford health insurance? Intimate in feeling, astonishing in scope, and impossible to put down, The Immortal Life of Henrietta Lacks captures the beauty and drama of scientific discovery, as well as its human consequences.